In conclusion, in individuals with T2DM with or without AD receiving background statin therapy, evolocumab significantly reduced LDL-C, non-HDL-C, ApoB, Lp(a), VLDL-C, and remnant cholesterol. This evidence concerns the gene APOB and Alzheimer disease.